Ongoing Projects
Completed Projects
Funding Agency: NIH/NCI
Award Mechanism: R01 (CA235677)
Award Name: Preventing an Incurable Disease: The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)
Role: PI (Peter Allen, M.D.)
Funding Agency: NIH/NCI
Award Mechanism: T32 (CA093245)
Award Name: Translational research in surgical oncology
Role: PI (Peter Allen, M.D.)
Funding Agency: NIH/NCI
Award Mechanism: R01 CA182076
Award Name: Biomarker validation for intraductal papillary mucinous neoplasms of the pancreas
Role: PI (Peter Allen, M.D.)
Funding Agency: NIH/NCI
Award Mechanism: U01 (CA152653)
Award Name: Detection of Pre-Invasive Pancreatic Cysts Using Protein and Glycan Biomarkers
Role: PI (Peter Allen, M.D.)
Funding Agency: Hopper-Belmont Foundation
Award Mechanism: Inspiration Award
Award Name: Profiling Hepatic Immune Populations to Target Occult Liver Metastases in Pancreatic Cancer
Role: PI (Daniel Nussbaum, M.D.)
Funding Agency: Duke Cancer Institute
Award Mechanism: Pilot Research Award
Award Name: Leveraging MDS Technology to Approach the “Needle in A Haystack” Problem of Occult Liver Metastasis in Pancreatic Adenocarcinoma
Role: Co-PI (Daniel Nussbaum, M.D.)
Funding Agency: Duke University Office of Physician-Scientist Development
Award Mechanism: Strong Start Award
Award Name: Deciphering Mechanisms of Hepatic Immunity Governing Pancreatic Cancer Liver Metastasis
Role: PI (Daniel Nussbaum, M.D.)
Funding Agency: NIH/NCI
Award Mechanism: R01 (CA208401)
Award Name: Protein and proteolytic activity biomarkers of early stage pancreatic cancer
Role: Co-PI (Peter Allen, M.D.)
Funding Agency: DoD/CDMRP
Award Mechanism: Idea Award (W81XWH-16-1-0271)
Award Name: Somatic mosaicism for cancer predisposition genes and pancreatic cancer
Role: Co-PI (Peter Allen, M.D.)
Funding Agency: NIH/NCI
Award Mechanism: U01 (CA086402)
Award Name: EDRN Pancreatic Cyst Reference Set
Role: Co-PI (Peter Allen, M.D.)
Funding Agency: NIH/NCI
Award Mechanism: R21 (CA158267)
Award Name: Antibody bead array technology for diagnosis of pre-invasive pancreatic cancer
Role: PI (Peter Allen, M.D.)
Funding Agency: Lustgarten Foundation for Pancreatic Cancer Research
Award Mechanism: Early Detection
Award Name: Serum and cyst fluid markers for the early detection of pancreatic cancer
Role: Co-PI (Peter Allen, M.D.)
Funding Agency: Novartis
Award Mechanism: Investigator-Initiated Trial
Award Name: Prospective randomized, double blind, placebo controlled trial of SOM230 for the reduction of post pancreatectomy fistula, leak and abscess
Role: PI (Peter Allen, M.D.)
Funding Agency: NIH/NCI
Award Mechanism: U01 (CA08496)
Award Name: Early Detection Research Network: Cyst fluid biomarkers in pre-malignant pancreatic cysts
Role: PI (Peter Allen, M.D.)
Funding Agency: Society of Surgical Oncology
Award Mechanism: Clinical Investigator Award
Award Name: Cyst fluid protein expression profiling for the identification of high-risk Intraductal papillary mucinous neoplasm of the pancreas
Role: PI (Peter Allen, M.D.)
Funding Agency: NIH/NCI
Award Mechanism: Core Grant Funding
Award Name: Pancreatic cancer pre-validation reference set for serum/plasma biomarkers
Role: Co-PI (Peter Allen, M.D.)
Funding Agency: Sanofi-Aventis
Award Mechanism: Investigator-Initiated Trial
Award Name: Phase II (Pilot) Study of neoadjuvant gemcitabine and oxaliplatin in patients with potentially resectable previously untreated pancreatic adenocarcinoma
Role: Co-PI (Peter Allen, M.D.)
Funding Agency: NIH/NCI
Award Mechanism: Early Stage Surgeon Scientist Program (3P30-CA014236-49S1)
Award Name: Deciphering Mechanisms of Hepatic Immunity Governing Pancreatic Cancer Liver Metastasis
Role: Participant (Daniel Nussbaum, M.D.)